Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 13/2022

17-08-2022 | Esophageal Cancer | ASO Author Reflections

ASO Author Reflections: Significance of Loss of Skeletal Muscle Mass During Neoadjuvant Chemotherapy in Older Patients with Esophageal Cancer

Authors: Tsuyoshi Harada, MSc, Tetsuya Tsuji, MD, PhD, Takeo Fujita, MD, PhD, FACS

Published in: Annals of Surgical Oncology | Issue 13/2022

Login to get access

Excerpt

The number of older patients with esophageal cancer has increased globally,1 necessitating development of novel treatments and supportive care for patients 65 years of age or older with esophageal cancer who have physical frailty and a heterogeneous aging process.2 Skeletal muscle mass (SMM) affects progression of the physical frailty, general health, and prognosis of older patients with cancer.3 Findings recently have shown that loss of SMM during neoadjuvant therapy affects the prognosis of individuals with locally advanced esophageal cancer.4 However, information regarding this phenomenon in older patients is limited. …
Literature
1.
Kamangar F, Nasrollahzadeh D, Safiri S, et al. The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(6):582–97.CrossRef
2.
Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy ASCO guideline for geriatric oncology. J Clin Oncol. 2018;36(22):2326–47.CrossRefPubMedPubMedCentral
3.
4.
Kamitani N, Migita K, Matsumoto S, et al. Association of skeletal muscle loss with the long-term outcomes of esophageal cancer patients treated with neoadjuvant chemotherapy. Surg Today. 2019;49:1022–28.CrossRefPubMed
5.
Metadata
Title
ASO Author Reflections: Significance of Loss of Skeletal Muscle Mass During Neoadjuvant Chemotherapy in Older Patients with Esophageal Cancer
Authors
Tsuyoshi Harada, MSc
Tetsuya Tsuji, MD, PhD
Takeo Fujita, MD, PhD, FACS
Publication date
17-08-2022
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 13/2022
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-022-12380-9

Other articles of this Issue 13/2022

Annals of Surgical Oncology 13/2022 Go to the issue

ASO Visual Abstract

ASO Visual Abstract: Prediction of Individual Lymph Node Metastatic Status in Esophageal Squamous Cell Carcinoma Using Routine CT Imaging: Comparison of Size-Based Measurements and Radiomics-Based Models

ASO Author Reflections

ASO Author Reflections: Insufficient Preoperative Smoking Cessation May Deteriorate Postoperative Prognosis for Esophageal Cancer

Reconstructive Oncology

Impact of Patient Primary Language upon Immediate Breast Reconstruction After Mastectomy

Thoracic Oncology

Radiomics with Artificial Intelligence for the Prediction of Early Recurrence in Patients with Clinical Stage IA Lung Cancer

ASO Research Letter

Soluble E-Cadherin as a Potential Biomarker in Hereditary Diffuse Gastric Cancer Syndrome

Breast Oncology

Who Are We Missing: Does Engagement in Patient-Reported Outcome Measures for Breast Cancer Vary by Age, Race, or Disease Stage?